Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00061945 · OUTCOME

Number of Participants Achieving Complete Remission

Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia · Source last updated 2022-05-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
9 years

What was measured

A complete remission (CR) requires the following: an absolute neutrophil count (segs and bands) \> 1500/μl, no circulating blasts, platelets \> 100,000/μl; bone marrow cellularity \> 20% with trilineage hematopoiesis, and \< 5% marrow blast cells, none of which appear neoplastic. All previous extramedullary manifestations of disease must be absent (e.g., lymphadenopathy, splenomegaly, skin or gum infiltration, testicular masses, or CNS involvement).

Analysis population: Three participants were deemed ineligible and excluded from this analysis.

Groups in this outcome

Phase I - Alemtuzumab and Combination Chemotherapy

See detailed description

Phase II - Alemtuzumab and Combination Chemotherapy

See detailed description

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Phase I - Alemtuzumab and Combination Chemotherapy116
Phase II - Alemtuzumab and Combination Chemotherapy181

Reported measurements

Source class 1
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Phase I - Alemtuzumab and Combination Chemotherapy92Not reportedNot reportedNot reportedNot reported
Phase II - Alemtuzumab and Combination Chemotherapy145Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        92
      2. group Id
        OG001
        value
        145
denoms
  1. counts
    1. group Id
      OG000
      value
      116
    2. group Id
      OG001
      value
      181
    units
    Participants
description
A complete remission (CR) requires the following: an absolute neutrophil count (segs and bands) \> 1500/μl, no circulating blasts, platelets \> 100,000/μl; bone marrow cellularity \> 20% with trilineage hematopoiesis, and \< 5% marrow blast cells, none of which appear neoplastic. All previous extramedullary manifestations of disease must be absent (e.g., lymphadenopathy, splenomegaly, skin or gum infiltration, testicular masses, or CNS involvement).
groups
  1. description
    See detailed description
    id
    OG000
    title
    Phase I - Alemtuzumab and Combination Chemotherapy
  2. description
    See detailed description
    id
    OG001
    title
    Phase II - Alemtuzumab and Combination Chemotherapy
param Type
NUMBER
population Description
Three participants were deemed ineligible and excluded from this analysis.
reporting Status
POSTED
time Frame
9 years
title
Number of Participants Achieving Complete Remission
type
POST_HOC
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice